B-cell Lymphoma
Showing 1 - 25 of 95
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)
Not yet recruiting
- B-cell Lymphoma
- CAR20(NAP)-T
- +2 more
-
Stockholm, Sweden
- +1 more
Aug 15, 2023
B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)
Recruiting
- B-Cell Leukemia
- +2 more
- Anti-CD19 Autologous CAR-T Cell Infusion
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023
Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)
Not yet recruiting
- Large B-cell Lymphoma
- B-cell Lymphoma
- Magrolimab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2023
B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)
Recruiting
- B-Cell Lymphoma
- +4 more
- 19(T2)28z1xx TRAC T cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023
B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)
Recruiting
- B-cell Lymphoma
- ASCT+CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- allogenic CD19-CAR-NK cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023
Mitochondrial dysfUnction:Key Player in Doxorubicin-induced
Not yet recruiting
- Doxorubicin Induced Cardiomyopathy
- +3 more
- 31-MRS at 7 Tesla (T)
-
Utrecht, Netherlands
- +1 more
Feb 7, 2023
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Normal Subjects and Disorders of Immune System and Cancer
Recruiting
- T-cell Lymphoma
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)
Active, not recruiting
- B-Cell Lymphoma
- TG-1801
- Ublituximab
-
Heidelberg, Victoria, Australia
- +2 more
Jan 20, 2023
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,
Active, not recruiting
- Multiple Myeloma
- +2 more
- Tiragolumab
- +3 more
-
Denver, Colorado
- +12 more
Jan 19, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin Trial in Worldwide (LOXO-338,
Active, not recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +6 more
-
Duarte, California
- +8 more
Jan 11, 2023
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))
Active, not recruiting
- B-Cell Lymphoma
- Non-Hodgkin Lymphoma
- Glofitamab
- +8 more
-
Birmingham, Alabama
- +23 more
Dec 2, 2022
B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)
Withdrawn
- B-cell Lymphoma
- B-cell Leukemia
- anti-CD19 UCAR-NK cells
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)
Not yet recruiting
- B-cell Lymphoma
- Relmacabtagene Autoleucel
- +2 more
-
Beijing, Beijing, China
- +1 more
Oct 19, 2022
B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)
Active, not recruiting
- B-cell Lymphoma
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022